Health
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Headline as filed by MarketWatch.
Compare coverage — 2 reports
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| MarketWatch | Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss |
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION. |
0m | marketwatch.com | First Page headline | ||
| CNBC Top News | FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound |
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes. |
14h | cnbc.com | Latest |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.